These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2108491)
1. Intravesical mitomycin C for carcinoma in situ of the urinary bladder. Hellsten S; Månsson W; Henrikson H; Idwall I; Lindholm K; Mikulowski P; Mårtensson S; Oldbring J Scand J Urol Nephrol; 1990; 24(1):35-8. PubMed ID: 2108491 [TBL] [Abstract][Full Text] [Related]
2. Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. Stricker PD; Grant AB; Hosken BM; Taylor JS J Urol; 1990 Jan; 143(1):34-5; discussion 35-6. PubMed ID: 2104637 [TBL] [Abstract][Full Text] [Related]
3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
4. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. Giesbers AA; Van Helsdingen PJ; Kramer AE Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144 [TBL] [Abstract][Full Text] [Related]
5. Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. Fukui I; Sekine H; Kihara K; Yamada T; Takeuchi S; Yokokawa M; Kawai T; Hosoda K; Ohwada F; Suzuki S J Urol; 1989 Mar; 141(3):531-4. PubMed ID: 2493099 [TBL] [Abstract][Full Text] [Related]
6. Topical mitomycin C therapy for carcinoma of the bladder. Stricker PD; Grant AB; Hosken BM; Taylor JS J Urol; 1987 Nov; 138(5):1164-6. PubMed ID: 3118056 [TBL] [Abstract][Full Text] [Related]
7. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder]. Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812 [TBL] [Abstract][Full Text] [Related]
8. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands. van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272 [No Abstract] [Full Text] [Related]
9. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa. Mobley WC; Loening SA; Narayana AS; Culp DA Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555 [TBL] [Abstract][Full Text] [Related]
10. Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. Minervini R; Cecchi M; Felipetto R; Viganò L; Pagni G Acta Urol Belg; 1994 Apr; 62(1):1-5. PubMed ID: 8197924 [TBL] [Abstract][Full Text] [Related]
11. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group. Rintala E; Jauhiainen K; Alfthan O Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270 [No Abstract] [Full Text] [Related]
12. Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later. Jakse G Eur Urol; 1984; 10(5):289-93. PubMed ID: 6440791 [TBL] [Abstract][Full Text] [Related]
13. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. Sekine H; Fukui I; Yamada T; Ohwada F; Yokokawa M; Ohshima H J Urol; 1994 Jan; 151(1):27-30. PubMed ID: 8254827 [TBL] [Abstract][Full Text] [Related]
15. Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. Minervini R; Felipetto R; Viganò L; Cecchi M Int Urol Nephrol; 1994; 26(4):437-42. PubMed ID: 8002217 [TBL] [Abstract][Full Text] [Related]
16. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group. Debruyne FM; van der Meijden AP; Franssen MP Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556 [No Abstract] [Full Text] [Related]
17. [Intravesical mitomycin for superficial tumors of the bladder: difficulties of cystoscopic monitoring]. Fourcade RO; Giuliano F Ann Urol (Paris); 1988; 22(6):404-6. PubMed ID: 3146942 [TBL] [Abstract][Full Text] [Related]
18. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. Sekine H; Fukui I; Yamada T; Yamada T; Kojima S; Ohshima H J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908 [TBL] [Abstract][Full Text] [Related]
19. [Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C]. Flüchter SH; Harzmann R; Erdmann D; Bichler KH Helv Chir Acta; 1982 Aug; 49(3-4):349-52. PubMed ID: 6813293 [No Abstract] [Full Text] [Related]
20. Chemotherapy for carcinoma in situ of the bladder. Jenkins BJ; England HR; Fowler CG; Tiptaft RC; Badenoch DF; Paris AM; Oliver RT; Blandy JP Br J Urol; 1988 Apr; 61(4):326-9. PubMed ID: 3133011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]